Genmab ASFRA:GE91 +0.93%93 Dividend Yield % is 0.00% as of Jun. 24, 2026. GuruFocus rates FRA:GE91 with a GF Score™ of 93/100 and a GF Value™ of €29.03 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 151 Biotechnology companies, Genmab AS ranks worse than 662250.99% on this metric.
As of today (2026-06-24), the Trailing Annual Dividend Yield of Genmab AS is 0.00%.
The historical rank and industry rank for Genmab AS's Dividend Yield % or its related term are showing as below:
FRA:GE91's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.51 * Ranked among companies with meaningful Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Genmab AS (FRA:GE91) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for Genmab AS's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:GE91 vs VRTX, REGN, ALNY: Dividend Yield % Comparison
For the Biotechnology subindustry, Genmab AS's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Genmab AS's Dividend Yield % falls into.
Genmab AS (FRA:GE91) has a Dividend Yield % of 0.00% as of Jun. 24, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Genmab AS and its competitors. According to the industry distribution chart, Genmab AS ranks #999999 out of 151 companies in the Biotechnology industry.
Is Genmab AS's Dividend Yield % too high?
Genmab AS's current Dividend Yield % is 0.00%. Based on the distribution chart, Genmab AS ranks #999999 out of 151 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Genmab AS has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #999999 out of 151 companies for Dividend Yield %. This places Genmab AS in the lower half of its industry. The industry median Dividend Yield % is 1.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.51, based on 151 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Genmab AS and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genmab AS's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (FRA:GE91) is currently considered Modestly Undervalued. The stock's GF Value™ is €29.03, compared to a current price of €21.80 — trading 24.9% below its estimated fair value. The current Dividend Yield % is 0.00%. Genmab AS's overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Genmab AS (FRA:GE91), the current Dividend Yield % is 0.00% as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (FRA:GE91) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of €21.80 is trading 24.9% below its estimated GF Value™ of €29.03.
GuruFocus considers Genmab AS to be Modestly Undervalued.
Key valuation signals for FRA:GE91:
Dividend Yield %: 0.00%
GF Value™: €29.03 vs. price of €21.80 (24.9% below fair value)
No single metric tells the full story. See the FRA:GE91 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
93GF Score
Get the complete analysis for FRA:GE91
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GE91 has been successfully added to your 
